Atlas Private Wealth Management Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

view original post

Atlas Private Wealth Management increased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 7.8% in the first quarter, HoldingsChannel.com reports. The fund owned 19,275 shares of the company’s stock after buying an additional 1,395 shares during the period. Johnson & Johnson comprises approximately 2.0% of Atlas Private Wealth Management’s investment portfolio, making the stock its 11th biggest holding. Atlas Private Wealth Management’s holdings in Johnson & Johnson were worth $3,416,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Magnolia Capital Management Ltd. raised its stake in shares of Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after buying an additional 55 shares during the last quarter. Howard Financial Services LTD. boosted its holdings in Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after buying an additional 57 shares during the last quarter. Capital Investment Counsel Inc boosted its holdings in shares of Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after purchasing an additional 59 shares during the last quarter. Kwmg LLC boosted its holdings in shares of Johnson & Johnson by 2.6% during the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after purchasing an additional 59 shares during the last quarter. Finally, Beaton Management Co. Inc. boosted its holdings in shares of Johnson & Johnson by 0.3% during the 4th quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock worth $3,806,000 after purchasing an additional 60 shares during the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

NYSE JNJ opened at $175.44 on Thursday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a market capitalization of $461.65 billion, a PE ratio of 23.64, a P/E/G ratio of 3.53 and a beta of 0.63. The company has a fifty day moving average of $176.74 and a two-hundred day moving average of $174.23. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.60 by $0.07. The business had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.59 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.23 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a $1.13 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.58%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.

Several research firms have recently commented on JNJ. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Finally, Raymond James boosted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.29.

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. Insiders have sold 78,161 shares of company stock valued at $13,895,302 in the last three months. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.